Skip to main content

Table 2 Clinical features of SSc patients.

From: The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy

Patients

Age

Sex

SSc type

Early/Late

Duration (years)

MRSS

N900

43

F

    

N901

43

F

    

N1003

26

M

    

N1016

35

F

    

S902

54

F

lcSSc

Early*

1

12

S903

39

F

dcSSc

Late

5

19

S904

33

F

dcSSc

Late

9

N/A

S1004

27

F

dcSSc

Late

10

26

S1066

21

M

dcSSc

Early

2

15

S1156

48

F

SSc/PM

Early

1

20

S1302

51

F

lcSSc

Early

2

4

  1. *early = < 2 years from first non-Raynaud symptom at the time of skin biopsy. Fibroblasts from N900-1016 and S902-1004 were used for real-time qPCR analysis. Fibroblasts from S1004-1302 were used for Western blot analysis. MRSS, Modified Rodnan skin score; SSc, systemic sclerosis.